Nadia Hindi

5.0k total citations
81 papers, 889 citations indexed

About

Nadia Hindi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Nadia Hindi has authored 81 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 19 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Nadia Hindi's work include Sarcoma Diagnosis and Treatment (64 papers), Vascular Tumors and Angiosarcomas (24 papers) and Cardiac tumors and thrombi (19 papers). Nadia Hindi is often cited by papers focused on Sarcoma Diagnosis and Treatment (64 papers), Vascular Tumors and Angiosarcomas (24 papers) and Cardiac tumors and thrombi (19 papers). Nadia Hindi collaborates with scholars based in Spain, Italy and France. Nadia Hindi's co-authors include Javier Martín‐Broto, David S. Moura, Silvia Stacchiotti, Paolo G. Casali, Javier Martínez‐Trufero, Alessandro Gronchi, Antonio Gutiérrez, Antonio López–Pousa, Claudia Valverde and Paola Collini and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Nadia Hindi

73 papers receiving 884 citations

Peers

Nadia Hindi
Jun Nishio Japan
Elena Conca Italy
Marie Karanian France
Jonathan Landa United States
Marta Barisella Italy
Dariusz Borys United States
Yosuke Morimitsu Japan
Joost M. van Gorp Netherlands
Josephine Issakov Israel
Mehdi Brahmi France
Jun Nishio Japan
Nadia Hindi
Citations per year, relative to Nadia Hindi Nadia Hindi (= 1×) peers Jun Nishio

Countries citing papers authored by Nadia Hindi

Since Specialization
Citations

This map shows the geographic impact of Nadia Hindi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Hindi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Hindi more than expected).

Fields of papers citing papers by Nadia Hindi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadia Hindi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Hindi. The network helps show where Nadia Hindi may publish in the future.

Co-authorship network of co-authors of Nadia Hindi

This figure shows the co-authorship network connecting the top 25 collaborators of Nadia Hindi. A scholar is included among the top collaborators of Nadia Hindi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadia Hindi. Nadia Hindi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Palmerini, Emanuela, Antonio López–Pousa, Giovanni Grignani, et al.. (2024). Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial. Cancer. 131(1). e35628–e35628. 6 indexed citations
2.
Martín‐Broto, Javier, Ricardo Fernández, M. Ferreira, et al.. (2024). Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma. Therapeutic Advances in Medical Oncology. 16. 2669780–2669780.
3.
Martín‐Broto, Javier, Robert Díaz Beveridge, David S. Moura, et al.. (2024). Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). Journal of Clinical Oncology. 43(3). 297–307. 11 indexed citations
4.
Attia, Steven, Víctor M. Villalobos, Nadia Hindi, et al.. (2023). Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas. Cancers. 15(19). 4871–4871. 1 indexed citations
5.
Hindi, Nadia, et al.. (2023). Antiangiogenics in Malignant Granular Cell Tumors: Review of the Literature. Cancers. 15(21). 5187–5187. 1 indexed citations
6.
Hindi, Nadia, Nadia N. Laack, Kelvin Hong, & Peter Hohenberger. (2023). Local Therapies for Metastatic Sarcoma: Why, When, and How?. American Society of Clinical Oncology Educational Book. 43(43). e390554–e390554. 2 indexed citations
7.
Hindi, Nadia, Jaime Carrillo, Pablo Luna, et al.. (2023). Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression. International Journal of Molecular Sciences. 24(1). 856–856. 3 indexed citations
8.
Martín‐Broto, Javier, Jerónimo Martínez-García, David S. Moura, et al.. (2023). Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A. Signal Transduction and Targeted Therapy. 8(1). 405–405. 15 indexed citations
9.
López-Álvarez, María, Cristina González‐Aguilera, David S. Moura, et al.. (2022). Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas. International Journal of Molecular Sciences. 24(1). 680–680. 2 indexed citations
10.
Martín‐Broto, Javier, Nadia Hindi, Giovanni Grignani, et al.. (2022). Experience with Second-Line Trabectedin in Daily Clinical Practice: Case Studies. Future Oncology. 18(sup30). 23–32. 2 indexed citations
11.
Martín‐Broto, Javier, Andrés Redondo, David S. Moura, et al.. (2022). A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 13(1). 6278–6278. 2 indexed citations
12.
Moura, David S., Antonio Fernández‐Serra, María López-Álvarez, et al.. (2020). CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study. Cancers. 12(5). 1128–1128. 3 indexed citations
13.
Hindi, Nadia, Antonio Gutiérrez, Inmaculada del Rincón, et al.. (2020). Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers. 12(12). 3740–3740. 15 indexed citations
14.
Fernández‐Serra, Antonio, David S. Moura, Silvia Calabuig‐Fariñas, et al.. (2020). Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. Cancers. 12(10). 2979–2979. 10 indexed citations
15.
Martín‐Broto, Javier, Nadia Hindi, Giovanni Grignani, et al.. (2020). Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. Journal for ImmunoTherapy of Cancer. 8(2). e001561–e001561. 117 indexed citations
16.
Obrador‐Hevia, Antònia, et al.. (2020). Cancer Stem Cells in Soft-Tissue Sarcomas. Cells. 9(6). 1449–1449. 16 indexed citations
17.
Constantinidou, Anastasia, Nicolas Sauvé, Silvia Stacchiotti, et al.. (2020). Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 5(4). e000787–e000787. 26 indexed citations
18.
Sanfilippo, Roberta, Robin L. Jones, Jean‐Yves Blay, et al.. (2019). Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clinical Cancer Research. 25(17). 5295–5300. 75 indexed citations
19.
Alemany, Regina, David S. Moura, Andrés Redondo, et al.. (2018). Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. Clinical Cancer Research. 24(21). 5239–5249. 22 indexed citations
20.
Hindi, Nadia, Paolo G. Casali, Carlo Morosi, et al.. (2015). Imatinib in advanced chordoma: A retrospective case series analysis. European Journal of Cancer. 51(17). 2609–2614. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun Nishio Breakdown of academic impact, for papers by Elena Conca Breakdown of academic impact, for papers by Marie Karanian Breakdown of academic impact, for papers by Jonathan Landa Breakdown of academic impact, for papers by Marta Barisella Breakdown of academic impact, for papers by Dariusz Borys Breakdown of academic impact, for papers by Yosuke Morimitsu Breakdown of academic impact, for papers by Joost M. van Gorp Breakdown of academic impact, for papers by Josephine Issakov Breakdown of academic impact, for papers by Mehdi Brahmi
Rankless by CCL
2026